Clinical trial
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized…
NCT00266136 · University Hospital Muenster, Other · Completed
Key facts
| NCT number | NCT00266136 |
|---|---|
| Title | Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) |
| Official title | Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose Chemotherapy With Stem Cell Transplantation |
| Lead sponsor | University Hospital Muenster, Other |
| Collaborators | Deutsche Krebshilfe e.V., Bonn (Germany) German Federal Ministry of Education and Research |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | Cytarabine, Thioguanine, Daunorubicin, Cyclophosphamide, G-CSF, Autologous stem cell transplantation, Allogeneic stem cell transplantation |
| Enrollment | 3,500 |
| Start date | Jun 1, 1999 |
| Primary completion | Jan 1, 2007 |
| Completion | Oct 1, 2012 |
| First posted | Dec 15, 2005 |
| Last update posted | Oct 26, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: